Contrary to our method, markers typically associated with FOLFOX resistance, such as ABCC2, have no clinical association with early relapse of CRC in patients receiving FOLFOX and cannot be used to create a reliable model [48]. The gene discussed is ABCC2; the disease is colorectal carcinoma.